Compare ORIC & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIC | ETON |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2020 | 2018 |
| Metric | ORIC | ETON |
|---|---|---|
| Price | $12.22 | $54.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | $19.73 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 1.0M | 521.1K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | ★ N/A | $139.22 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $7.23 | $14.27 |
| 52 Week High | $14.93 | $66.37 |
| Indicator | ORIC | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 53.69 |
| Support Level | $10.67 | $15.75 |
| Resistance Level | $14.27 | $66.37 |
| Average True Range (ATR) | 0.59 | 2.59 |
| MACD | -0.21 | -1.19 |
| Stochastic Oscillator | 33.05 | 16.08 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.